XTRA:MRKPharmaceuticals
Why Merck KGaA (XTRA:MRK) Is Up 6.6% After Beating Q4 Profitability Forecasts And What's Next
In the past year, Germany’s Merck KGaA reported that its 2014 group sales rose 3.7%, while fourth-quarter EBITDA excluding one-offs increased 10.5%, both ahead of analyst forecasts.
This stronger-than-expected revenue and earnings performance highlighted Merck KGaA’s operational discipline and demand resilience across its core science and technology businesses.
We’ll now examine how this earnings beat, particularly the stronger fourth-quarter profitability, could influence Merck KGaA’s...